The Medical Letter - 2012
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Year:    Publication:      2012 Annual Index: U.S. English | Canadian English
January 9, 2012 (Issue 1381)  
January 23, 2012 (Issue 1382)  
February 6, 2012 (Issue 1383)  
February 20, 2012 (Issue 1384)  
  • Salt Restriction   
    The average daily intake of sodium in the US is about 3400 mg. Dietary guidelines recommend reducing it to 50 years old. Salt reduction lowers blood pressure, and lowering blood pressure reduces...
  • Zolpidem Oral Spray (Zolpimist) for Insomnia   
    Zolpidem oral spray (Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate (Ambien, and others), has been approved by the FDA for short-term treatment...
  • Deferiprone (Ferriprox) for Iron Overload   
    The FDA has approved deferiprone (de fer’ i prone; Ferriprox – ApoPharma), an oral chelating agent available in Europe since 1999, for use as a second-line treatment of iron overload...
  • In Brief: 5-HTP for Depression   
    A Medical Letter reader asked about the use of the nutritional supplement 5-hydroxytryptophan (5-HTP) for treatment of depression. It is sold in health food stores, pharmacies and on-line for many...
March 5, 2012 (Issue 1385)  
March 19, 2012 (Issue 1386)  
April 2, 2012 (Issue 1387)  
April 16, 2012 (Issue 1388)  
April 30, 2012 (Issue 1389)  
May 14, 2012 (Issue 1390)  
May 28, 2012 (Issue 1391)  
June 11, 2012 (Issue 1392)  
June 25, 2012 (Issue 1393)  
July 9, 2012 (Issue 1394)  
July 23, 2012 (Issue 1395)  
August 6, 2012 (Issue 1396)  
  • PSA Reconsidered   
    Three recent publications have focused attention once more on the contentious question of whether men should be screened for prostate cancer by measuring serum concentrations of prostate specific...
  • Ivermectin (Sklice) Topical Lotion for Head Lice   
    The FDA has approved the antiparasitic drug ivermectin in a 0.5% lotion (Sklice – Sanofi Pasteur) as a single-use topical treatment for head lice in patients ≥6 months old. Oral...
  • Tablet Splitting   
    Breaking drug tablets in half is a common practice. Since our last article on this subject, some new data have become available.
  • In Brief: Truvada for HIV Prevention   
    Truvada (Gilead), an oral fixed-dose combination of the antiretrovirals emtricitabine and tenofovir disoproxil fumarate frequently used for treatment of HIV infection,1 has now also been...
  • Addendum: What Comes After Metformin for Type 2 Diabetes?   
    Several readers have raised questions about the statement in our recent article (Med Lett Drugs Ther 2012; 54:58) that long-acting insulins, like metformin and sulfonylureas, have been shown to...
August 20, 2012 (Issue 1397)  
  • Ezogabine (Potiga) for Epilepsy   
    The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine...
  • Prosthetic Heart Valves   
    Prosthetic heart valves have been used effectively in patients with mitral and aortic valvular heart disease for more than 50 years, but no replacement valve developed to date is suitable for all...
  • Addendum: Cost of Drugs for Acute Cystitis   
    A reader suggested that our July 23 article on Drugs for Urinary Tract Infection (Med Lett Drugs Ther 2012; 54:57)1 should have included information on the cost of the drugs we...
  • In Brief: Transdermal Rotigotine (Neupro)   
    A patch formulation of the non-ergot dopamine agonist rotigotine (Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment...
September 3, 2012 (Issue 1398)  
  • Two Drugs for Weight Loss   
    In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai)...
  • Citalopram (Celexa) and QT Interval Prolongation   
    The FDA has asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) antidepressant citalopram (Celexa, and others) to revise the labeling of the drug to include new...
September 17, 2012 (Issue 1399)  
  • Prevention and Treatment of Pertussis   
    The CDC has reported that many states are experiencing a higher-than-usual incidence of pertussis this year. The highest incidence has been in infants, but the disease has also occurred in older...
  • Endocarditis Prophylaxis for Dental Procedures   
    Since 2007, antimicrobial prophylaxis for dental procedures has been recommended only for patients at highest risk of severe consequences from infective endocarditis. There is no indication that...
  • Insect Repellents   
    Superseded by The Medical Letter "Insect Repellents" - Issue 1628, July 12, 2021The CDC has received a record number of reports of West Nile virus infection this year – 1993 as...
  • Correction: Two New Drugs for Weight Loss   
    (Med Lett Drugs Ther 2012; 54:69) On page 71 in the "Drug Interactions" paragraph, the last sentence should read: "Phentermine is contraindicated while taking, and for 14 days after stopping, a...
October 1, 2012 (Issue 1400)  
October 15, 2012 (Issue 1401)  
October 29, 2012 (Issue 1402)  
November 12, 2012 (Issue 1403)  
  • New Drugs for Multiple Sclerosis   
    In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide (Aubagio – Genzyme)...
  • Linaclotide (Linzess) for Constipation   
    Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest), a guanylate cyclase-C receptor agonist, was recently approved by the FDA for oral treatment of chronic...
November 26, 2012 (Issue 1404)  
December 10, 2012 (Issue 1405)  
December 24, 2012 (Issue 1406)